Biomea Fusion, Inc. (BMEA) Earnings Call Transcripts
Biomea Fusion, Inc.'s Latest Earnings Call - March 30, 2026
In Q1 FY2026, Biomea Fusion, Inc. focused on its lead program, icovamenib, a menin inhibitor for diabetes treatment. Revenue and earnings were not explicitly discussed, and no guidance changes were announced. The call highlighted the potential of icovamenib to redefine diabetes treatment by preserving pancreatic beta cells. Management emphasized the drug's safety profile and its synergistic effect with GLP-1 therapies, indicating a significant market opportunity.
Reported metrics
| Metric | Value |
|---|---|
| IcovaMenib A1c Reduction | Up to 1.5% A1c reduction (positive) |
| COVALENT 111 Trial Results | 1.2% A1c reduction in severe insulin-deficient patients (positive) |
| COVALENT 211 and 212 Enrollment | 60 patients targeted for each trial (neutral) |
| BMF 650 Weight Loss | 3% to 5% weight loss after 4 weeks (neutral) |
Guidance from management
Management aims to complete enrollment for COVALENT 211 and 212 trials within 3 months and expects data readouts by year-end 2026. No changes to financial guidance were provided.
What management said
No, it's cool. I mean, let me show it to you because -- let me see if I can -- yes, I can share. Look at this right here. So this is the paper you just mentioned, which is the original paper on the right-hand side from 2007. And this is in our deck. But if you -- in this slide here, what we're showing here is something that...
My apologies. What I was saying is that the Stanford study showed that prolactin downregulates menin. Menin because it normally inhibits beta cell proliferation, once it's inhibited, it allows the beta cells to increase in number and avoid pregnancy associated diabetes. It's also interesting that epidemiologic studies have followed women and segregated women who had live births, those who did or did not breast feed. ...
What analysts pressed on
Analysts questioned the variability in A1c reduction across different dosing regimens and the potential impact of adverse events. There was also interest in the broader applicability of icovamenib in the crowded diabetes market.
Main topics on the call
- IcovaMenib's Mechanism of Action — IcovaMenib targets menin, a protein that regulates pancreatic islet growth. Management highlighted its potential to restore beta cell function, with preclinical studies showing increased insulin production and glucose ab...
- Synergy with GLP-1 Therapies — IcovaMenib showed enhanced effects when combined with GLP-1 therapies, potentially delaying insulin dependence. 'The pathway of having a GLP-1 receptor agonist on board is sensitized to the use of menin.'
- Clinical Trial Progress — COVALENT 211 and 212 trials are enrolling, focusing on insulin-deficient and GLP-1 failing patients. Management aims for data readouts by year-end 2026. 'Our goal is to finish the 26 weeks data readout of the last patien...
- Type 1 Diabetes Potential — IcovaMenib is being tested in type 1 diabetes, with data expected in Q2 2026. The focus is on preserving beta cell function even in later stages of the disease. 'We asked a different question... can we have an effect the...
Read the full Biomea Fusion, Inc. transcript (March 30, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Biomea Fusion, Inc.
Biomea Fusion, Inc. (BMEA) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 22 calls on record spanning January 11, 2021 to May 5, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 22 Biomea Fusion, Inc. earnings call transcripts on record, spanning January 11, 2021 to May 5, 2026. Based on this history, Biomea Fusion, Inc. reports quarterly. The most recent call on file is dated May 5, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- BMEA
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 22
- First call
- January 11, 2021
- Most recent
- May 5, 2026
- Reporting cadence
- quarterly